Everett Harris & Co. CA Boosts Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

Everett Harris & Co. CA raised its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 2.6% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 14,506 shares of the medical research company’s stock after acquiring an additional 362 shares during the quarter. Everett Harris & Co. CA’s holdings in Thermo Fisher Scientific were worth $7,546,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in TMO. Clear Creek Financial Management LLC lifted its stake in shares of Thermo Fisher Scientific by 211.7% in the 4th quarter. Clear Creek Financial Management LLC now owns 2,104 shares of the medical research company’s stock valued at $1,095,000 after purchasing an additional 1,429 shares during the period. Heck Capital Advisors LLC purchased a new stake in Thermo Fisher Scientific in the fourth quarter worth about $567,000. Austin Private Wealth LLC boosted its position in shares of Thermo Fisher Scientific by 12.0% in the 4th quarter. Austin Private Wealth LLC now owns 786 shares of the medical research company’s stock worth $409,000 after purchasing an additional 84 shares in the last quarter. Caprock Group LLC increased its position in Thermo Fisher Scientific by 1.5% during the 4th quarter. Caprock Group LLC now owns 10,062 shares of the medical research company’s stock valued at $5,239,000 after buying an additional 148 shares in the last quarter. Finally, Alta Wealth Advisors LLC grew its stake in shares of Thermo Fisher Scientific by 9.0% in the fourth quarter. Alta Wealth Advisors LLC now owns 948 shares of the medical research company’s stock worth $493,000 after acquiring an additional 78 shares during the last quarter. 89.23% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 9,000 shares of the stock in a transaction that occurred on Friday, November 8th. The stock was sold at an average price of $552.86, for a total transaction of $4,975,740.00. Following the completion of the transaction, the chief executive officer now owns 14,608 shares of the company’s stock, valued at $8,076,178.88. This represents a 38.12 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Over the last quarter, insiders have sold 29,000 shares of company stock worth $15,859,540. 0.34% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several research firms recently issued reports on TMO. Citigroup upped their price objective on Thermo Fisher Scientific from $600.00 to $650.00 and gave the company a “neutral” rating in a research report on Friday. TD Cowen lifted their target price on shares of Thermo Fisher Scientific from $656.00 to $686.00 in a research report on Tuesday, October 22nd. Royal Bank of Canada cut their price objective on Thermo Fisher Scientific from $767.00 to $718.00 and set an “outperform” rating for the company in a report on Thursday, October 24th. UBS Group raised their price objective on shares of Thermo Fisher Scientific from $700.00 to $715.00 and gave the stock a “buy” rating in a report on Friday. Finally, Wells Fargo & Company increased their target price on shares of Thermo Fisher Scientific from $660.00 to $680.00 and gave the stock an “overweight” rating in a report on Friday. Four equities research analysts have rated the stock with a hold rating and nineteen have issued a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $655.64.

Thermo Fisher Scientific Stock Performance

TMO stock opened at $598.40 on Friday. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.63 and a quick ratio of 1.26. The business has a 50-day moving average price of $539.66 and a 200 day moving average price of $570.59. Thermo Fisher Scientific Inc. has a 1-year low of $493.30 and a 1-year high of $627.88. The company has a market capitalization of $228.89 billion, a P/E ratio of 37.52, a PEG ratio of 3.89 and a beta of 0.76.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Thursday, January 30th. The medical research company reported $6.10 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.94 by $0.16. Thermo Fisher Scientific had a net margin of 14.48% and a return on equity of 17.49%. As a group, equities research analysts forecast that Thermo Fisher Scientific Inc. will post 21.69 EPS for the current fiscal year.

Thermo Fisher Scientific announced that its Board of Directors has initiated a stock repurchase program on Friday, November 15th that allows the company to buyback $4.00 billion in outstanding shares. This buyback authorization allows the medical research company to reacquire up to 2% of its shares through open market purchases. Shares buyback programs are generally an indication that the company’s leadership believes its stock is undervalued.

Thermo Fisher Scientific Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, January 15th. Stockholders of record on Friday, December 13th were issued a $0.39 dividend. The ex-dividend date was Friday, December 13th. This represents a $1.56 annualized dividend and a dividend yield of 0.26%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 9.78%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.